Cargando…
The incretin/glucagon system as a target for pharmacotherapy of obesity
Obesity is a chronic, multifactorial, relapsing disease. Despite multicomponent lifestyle interventions, including pharmacotherapy, maintaining bodyweight loss is challenging for many people. The pathophysiology of obesity is complex, and currently approved pharmacotherapies only target a few of the...
Autores principales: | Del Prato, Stefano, Gallwitz, Baptist, Holst, Jens Juul, Meier, Juris J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286339/ https://www.ncbi.nlm.nih.gov/pubmed/34713962 http://dx.doi.org/10.1111/obr.13372 |
Ejemplares similares
-
Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy
por: Cattaneo, Mattia, et al.
Publicado: (2019) -
Cardiovascular Pharmacotherapy Focus
por: Avanzas, Pablo
Publicado: (2019) -
Review of pharmacotherapy for smoking cessation in patients with schizophrenia
por: Shawen, Avery E., et al.
Publicado: (2018) -
The Daily Therapy With L-Arginine 2,500 mg and Tadalafil 5 mg in Combination and in Monotherapy for the Treatment of Erectile Dysfunction: A Prospective, Randomized Multicentre Study
por: Gallo, Luigi, et al.
Publicado: (2020) -
Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis
por: Shin, Young Eun, et al.
Publicado: (2023)